IDegLira Improves Cardiovascular Risk Markers in Patients with Type 2 Diabetes Uncontrolled on Basal Insulin: Analyses of DUAL II and DUAL V

被引：0
|
作者：
Vilsboll, Tina
Blevins, Thomas C.
Bode, Bruce
Leiter, Lawrence A.
Poulter, Neil
Thurman, Jerry
Agner, Bue F. Ross
Lehmann, Lucine
Jaeckel, Elmar
机构：
来源：
DIABETES | 2017年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
983-P
引用
收藏
页码：A255 / A255
页数：1
相关论文
共 50 条
  • [1] IDegLira improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin: analyses of DUAL II and DUALV
    Vilsboll, T.
    Blevins, T.
    Bode, B. W.
    Leiter, L. A.
    Poulter, N.
    Thurman, J.
    Agner, B. F. R.
    Lehmann, L.
    Jaeckel, E.
    [J]. DIABETOLOGIA, 2017, 60 : S52 - S52
  • [2] Fixed-ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin
    Vilsboll, Tina
    Blevins, Thomas C.
    Jodar, Esteban
    Poulter, Neil
    Tentolouris, Nikolaos
    Agner, Bue F. Ross
    Lehmann, Lucine
    Leiter, Lawrence A.
    [J]. DIABETES OBESITY & METABOLISM, 2019, 21 (06): : 1506 - 1512
  • [3] Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial
    Billings, Liana K.
    Doshi, Ankur
    Gouet, Didier
    Oviedo, Alejandra
    Rodbard, Helena W.
    Tentolouris, Nikolaos
    Gron, Randi
    Halladin, Natalie
    Jodar, Esteban
    [J]. DIABETES CARE, 2018, 41 (05) : 1009 - 1016
  • [4] IDegLira Improves Glycemic Control in Japanese Patients with Uncontrolled Type 2 Diabetes on Premixed Insulin Therapy
    Hirotaka Watada
    Bue F. Ross Agner
    Ankur Doshi
    Lars Bardtrum
    Mattis Flyvholm Ranthe
    Liana K. Billings
    [J]. Diabetes Therapy, 2020, 11 : 331 - 339
  • [5] IDegLira Improves Glycemic Control in Japanese Patients with Uncontrolled Type 2 Diabetes on Premixed Insulin Therapy
    Watada, Hirotaka
    Agner, Bue F. Ross
    Doshi, Ankur
    Bardtrum, Lars
    Ranthe, Mattis Flyvholm
    Billings, Liana K.
    [J]. DIABETES THERAPY, 2020, 11 (01) : 331 - 339
  • [6] Effect of pramlintide as an adjunct to basal insulin on markers of cardiovascular risk in patients with type 2 diabetes
    Wysham, Carol
    Lush, Cameron
    Zhang, Bei
    Maier, Holly
    Wilhelim, Ken
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (01) : 79 - 85
  • [7] Efficacy and Safety of IDegLira in Participants with Type 2 Diabetes in India Uncontrolled on Oral Antidiabetic Drugs and Basal Insulin: Data from the DUAL Clinical Trial Program
    Khunti, Kamlesh
    Mohan, Viswanathan
    Jain, Sunil M.
    Boesgaard, Trine Wellov
    Begtrup, Kamilla
    Sethi, Bipin
    [J]. DIABETES THERAPY, 2017, 8 (03) : 673 - 682
  • [8] Efficacy and Safety of IDegLira in Participants with Type 2 Diabetes in India Uncontrolled on Oral Antidiabetic Drugs and Basal Insulin: Data from the DUAL Clinical Trial Program
    Kamlesh Khunti
    Viswanathan Mohan
    Sunil M. Jain
    Trine Welløv Boesgaard
    Kamilla Begtrup
    Bipin Sethi
    [J]. Diabetes Therapy, 2017, 8 : 673 - 682
  • [9] Effect of pramlintide treatment on markers of cardiovascular risk in patients with type 2 diabetes using basal insulin
    Lush, C.
    Zhang, B.
    Maggs, D.
    Darsow, T.
    Kolterman, O.
    [J]. DIABETOLOGIA, 2007, 50 : S514 - S514
  • [10] Cost Effectiveness of IDegLira vs. Alternative Basal Insulin Intensification Therapies in Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in a UK Setting
    Melanie J. Davies
    Divina Glah
    Barrie Chubb
    Gerasimos Konidaris
    Phil McEwan
    [J]. PharmacoEconomics, 2016, 34 : 953 - 966
12345